Myoinositol

ApprovedSmall molecule

SSohag University

Myoinositol is one of 114 small molecule programs targeting Ovarian Reserve. It is currently in Approved.

Indications

Total Trials

Active Trials

113

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian ReserveActive, not recruiting

Polycystic Ovary SyndromeActive, not recruiting

ObesityActive, not recruiting

GrowthActive, not recruiting

Ovarian ReservePhase 3

Active, not recruiting

Polycystic Ovary SyndromePhase 2/Phase 3

Active, not recruiting

ObesityApproved

Active, not recruiting

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

Myoinositol

SSohag University

Approved

1 2

Actemra

Roche

Preclinical

2 3

Avapro

Sanofi

Preclinical

1 4

Amidate

Pfizer

Preclinical

—5

Calciferol

Alnylam Pharmaceuticals

Adenocard

Activella

Colcrys

Alnylam Pharmaceuticals

Oxycontin

1 10

Advil

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Not yet recruiting

Metformin

NCT07459595

Clinical

Trials by Indication[1]

Polycystic Ovary Syndrome2 trials

Evaluation of the Mixture Myoinositol:D-chiro-inositol 3.6:1 in Women With Polycystic Ovary Syndrome

Completed·BBiosearch S.A.·Phase 2/3·NCT03201601·60 enrolled

Myo-inositol Versus Metformin in Obese Women With Polycystic Ovary Syndrome

Completed·—·N/A·NCT01791647·40 enrolled

Metformin2 trials

Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease: A Comparative Study

Not yet recruiting·FFatima Tariq·Phase 1·NCT07459595·60 enrolled

Impact of Myo-Inositol Alone vs Myo-Inositol Plus Metformin on Conception, Adherence, and Tolerability in PCOS

Completed·—·Phase 3·NCT07323589·120 enrolled

Polycystic Ovarian Syndrome1 trial

Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients

Not yet recruiting·—·Phase 3·NCT06405243·100 enrolled

Ovarian Reserve1 trial

of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve

Not yet recruiting·—·Phase 3·NCT06405204·200 enrolled

Polycystic Ovarian Syndrome (PCOS)1 trial

Myoinositol vs. Metformin for Polycystic Ovarian Syndrome (PCOS): Impact on Metabolic Health and Fertility

Completed·—·N/A·NCT07058675·156 enrolled

3 more indications

Growth1 trial

Transplacental Gradients and Transport in Intrauterine Growth Restricted (IUGR) Pregnancies Compared to Normal Pregnancies.

Terminated·UUniversity of Colorado, Denver·N/A·NCT02397291·24 enrolled

Outcome1 trial

The Effect of In-vitro Myoinositol Supplementation of Human Sperm on the Outcome of Cryopreservation

Completed·SSohag University·Phase 1/2·NCT03153436·41 enrolled

Obesity1 trial

ZIMBA: Clinical Trial in Paediatric Obesity

Completed·AAzienda Ospedaliero Universitaria Maggiore della Carita·Phase 4·NCT03283813·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Myoinositol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Myoinositol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Myoinositol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sohag University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSohag University

Myoinositol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Polycystic Ovary Syndrome2 trials

Metformin2 trials

Polycystic Ovarian Syndrome1 trial

Ovarian Reserve1 trial

Polycystic Ovarian Syndrome (PCOS)1 trial

Growth1 trial

Outcome1 trial

Obesity1 trial

References

Drug Info

Quick Facts

Related News